F-10POS: Oncolytics Biotech Deregisters Unsold Securities
Deregistration Statement
Oncolytics Biotech Inc. has filed post-effective amendments to withdraw multiple Form F-10 registration statements for unsold securities.
Summary
- Oncolytics Biotech Inc. filed Post-Effective Amendment No. 1 to several Form F-10 Registration Statements with the U.S. Securities and Exchange Commission.
- The company is withdrawing these registration statements, including all amendments and exhibits, with respect to the unsold portion of securities registered thereon.
- The withdrawn registration statements, initially filed between February 2, 2007, and July 25, 2024, covered various securities including units, common shares, subscription receipts, warrants, and debt securities.
- The deregistration is proposed to become effective on April 7, 2026, at 10:00 p.m. Eastern time.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing, reflecting a procedural cleanup of previously registered but unsold securities, with no direct positive or negative implications for the company's current operations or financial health.
Future Outlook
NA
Management Comments
- The Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-10 and has duly caused these post-effective amendments to be signed on its behalf by the undersigned, thereunto duly authorized.
Industry Context
StockSavvy.ai notes that this is a routine administrative filing common for companies that have completed or decided not to proceed with certain offerings, and it does not reflect on the company's operational performance or strategic direction within the biotech industry.
Stakeholder Impact
- Shareholders: No direct impact on current share value or ownership structure from this administrative deregistration. It clarifies the status of previously registered but unsold securities.
Next Steps
- The deregistration is proposed to become effective on April 7, 2026, at 10:00 p.m. Eastern time.
Key Dates
| Date | Description |
|---|---|
| 2007-02-02 | Initial filing of Registration Statement No. 333-140460 for units. |
| 2007-02-08 | Initial filing of Registration Statement No. 333-140529 for common shares. |
| 2008-06-06 | Initial filing of Registration Statement No. 333-151513 for various securities. |
| 2010-06-02 | Initial filing of Registration Statement No. 333-167250 for various securities. |
| 2012-06-21 | Initial filing of Registration Statement No. 333-182260 for various securities. |
| 2014-07-25 | Initial filing of Registration Statement No. 333-197633 for various securities. |
| 2018-04-25 | Initial filing of Registration Statement No. 333-224432 for various securities. |
| 2020-06-08 | Initial filing of Registration Statement No. 333-239025 for various securities. |
| 2022-06-10 | Initial filing of Registration Statement No. 333-265510 for various securities. |
| 2024-07-25 | Initial filing of Registration Statement No. 333-281009 for various securities. |
| 2026-03-31 | Filing date of the Post-Effective Amendment No. 1 to Form F-10. |
| 2026-04-07 | Proposed effective date of the deregistration at 10:00 p.m. Eastern time. |
Recommendation
holdThis filing is purely administrative, concerning the deregistration of previously registered but unsold securities. It provides no new information regarding the company's operational performance, financial outlook, or strategic direction that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate as existing investment theses remain unchanged.
Keywords
Oncolytics Biotech, F-10POS, SEC filing, Deregistration, Securities Withdrawal, Common Shares, Warrants, Debt Securities, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.